Drug Type Small molecule drug |
Synonyms Chlorthalidone/telmisartan, Telmisartan/chlortalidone, Telmisartan/Chlorthalidone + [3] |
Target |
Action antagonists, inhibitors |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (05 Mar 2026), |
Regulation- |
Molecular FormulaC14H11ClN2O4S |
InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N |
CAS Registry77-36-1 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Essential Hypertension | South Korea | 05 Mar 2026 |





